narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide
PreclinicalSmall molecule
narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide is one of 27 small molecule programs targeting Neoadjuvant Chemotherapy. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Neoadjuvant Chemotherapy
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Taxol
TevaPhase 3
Eloxatin
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Adriamycin
PfizerPhase 2
Abraxane
Bristol-Myers SquibbPhase 2
Neoadjuvant Chemotherapy
JJapan Clinical Oncology Group
Phase 3
Beyfortus
BeiGenePhase 2
Alinamin
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details